Gliomas are the most frequently occurring brain tumors with a heterogeneous molecular background. The molecular subgrouping of gliomas more prognostically stratifies patients into distinct groups compared with conventional histological classification. The most important molecules for the subtype diagnosis of diffuse gliomas are mutations of isocitrate dehydrogenase (IDH), TERT promoter, and α-thalassemia/mental-retardation-syndrome-X-linked (ATRX) and the codeletion of 1p/19q. Among them, IDH and ATRX mutations can be diagnosed using specific monoclonal antibodies (mAbs). We have developed many mAbs against IDH mutants, including HMab-1/HMab-2 against IDH1-R132H and multispecific mAbs MsMab-1/MsMab-2 against IDH1/2 mutations. In contrast, highly sensitive mAbs against ATRX remain to be established. In this study, we immunized mice with recombinant human ATRX and developed a novel mAb, AMab-6. The dissociation constant of AMab-6 was determined to be 9.7 × 10−10 M, indicating that the binding affinity of AMab-6 is very high. Furthermore, AMab-6 sensitively detects ATRX in Western blot and immunohistochemical analyses, indicating that AMab-6 could become the standard marker to determine the ATRX mutation status of gliomas in immunohistochemical analyses.
Get full access to this article
View all access options for this article.
References
1.
ReussDE, SahmF, SchrimpfD, WiestlerB, CapperD, KoelscheC, SchweizerL, KorshunovA, JonesDT, HovestadtV, MittelbronnM, SchittenhelmJ, Herold-MendeC, UnterbergA, PlattenM, WellerM, WickW, PfisterSM, and von DeimlingA: ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol, 2015; 129:133–146.
2.
WellerM, WeberRG, WillscherE, RiehmerV, HentschelB, KreuzM, FelsbergJ, BeyerU, Loffler-WirthH, KaulichK, SteinbachJP, HartmannC, GramatzkiD, SchrammJ, WestphalM, SchackertG, SimonM, MartensT, BostromJ, HagelC, SabelM, KrexD, TonnJC, WickW, NoellS, SchlegelU, RadlwimmerB, PietschT, LoefflerM, von DeimlingA, BinderH, and ReifenbergerG: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol, 2015; 129:679–693.
AritaH, NaritaY, YoshidaA, HashimotoN, YoshimineT, and IchimuraK: IDH1/2 mutation detection in gliomas. Brain Tumor Pathol, 2015; 32:79–89.
5.
LouisDN, PerryA, BurgerP, EllisonDW, ReifenbergerG, von DeimlingA, AldapeK, BratD, CollinsVP, EberhartC, Figarella-BrangerD, FullerGN, GiangasperoF, GianniniC, HawkinsC, KleihuesP, KorshunovA, KrosJM, Beatriz LopesM, NgHK, OhgakiH, PaulusW, PietschT, RosenblumM, RushingE, SoylemezogluF, WiestlerO, WesselingP, and International Society Of Neuropathology—Haarlem: International Society Of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol, 2014; 24:429–435.
6.
LouisDN, PerryA, ReifenbergerG, von DeimlingA, Figarella-BrangerD, CaveneeWK, OhgakiH, WiestlerOD, KleihuesP, and EllisonDW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol, 2016; 131:803–820.
7.
TakanoS, IshikawaE, SakamotoN, MatsudaM, AkutsuH, NoguchiM, KatoY, YamamotoT, and MatsumuraA: Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol, 2016; 33:107–116.
8.
EbrahimiA, SkardellyM, BonzheimI, OttI, MuhleisenH, EckertF, TabatabaiG, and SchittenhelmJ: ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun, 2016; 4:60.
9.
TakanoS, TianW, MatsudaM, YamamotoT, IshikawaE, KanekoMK, YamazakiK, KatoY, and MatsumuraA: Detection of IDH1 mutation in human gliomas: Comparison of immunohistochemistry and sequencing. Brain Tumor Pathol, 2011; 28:115–123.
10.
TanboonJ, WilliamsEA, and LouisDN: The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol, 2016; 75:4–18.
11.
SuzukiH, AokiK, ChibaK, SatoY, ShiozawaY, ShiraishiY, ShimamuraT, NiidaA, MotomuraK, OhkaF, YamamotoT, TanahashiK, RanjitM, WakabayashiT, YoshizatoT, KataokaK, YoshidaK, NagataY, Sato-OtsuboA, TanakaH, SanadaM, KondoY, NakamuraH, MizoguchiM, AbeT, MuragakiY, WatanabeR, ItoI, MiyanoS, NatsumeA, and OgawaS: Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet, 2015; 47:458–468.
12.
KatoY: Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol, 2015; 32:3–11.
13.
KatoY, JinG, KuanCT, McLendonRE, YanH, and BignerDD: A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun, 2009; 390:547–551.
14.
KatoY, and KanekoMK: Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172 W mutation. Biochem Biophys Res Commun, 2013; 433:374–378.
15.
KatoY, NatsumeA, and KanekoMK: A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun, 2013; 432:564–567.
16.
KanekoMK, MoritaS, TsujimotoY, YanagiyaR, NasuK, SasakiH, HozumiY, GotoK, NatsumeA, WatanabeM, KumabeT, TakanoS, and KatoY: Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun, 2013; 432:40–45.
17.
KanekoMK, TianW, TakanoS, SuzukiH, SawaY, HozumiY, GotoK, YamazakiK, KitanakaC, and KatoY: Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun, 2011; 406:608–613.
18.
KanekoMK, TsujimotoY, HozumiY, GotoK, and KatoY: Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132 L mutations. Monoclon Antib Immunodiagn Immunother, 2013; 32:224–228.
19.
LiuX, KatoY, KanekoMK, SugawaraM, OgasawaraS, TsujimotoY, NaganumaY, YamakawaM, TsuchiyaT, and TakagiM: Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med, 2013; 2:803–814.
20.
TakanoS, KatoY, YamamotoT, LiuX, IshikawaE, KanekoMK, OgasawaraS, MatsudaM, NoguchiM, and MatsumuraA: Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas. Brain Tumor Pathol, 2015; 32:169–175.
21.
TakanoS, KatoY, YamamotoT, KanekoMK, IshikawaE, TsujimotoY, MatsudaM, NakaiK, YanagiyaR, MoritaS, TsuboiK, and MatsumuraA: Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol, 2012; 108:361–373.
22.
FujiiY, OgasawaraS, OkiH, LiuX, KanekoMK, TakanoS, and KatoY: A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochem Biophys Res Commun, 2015; 466:733–739.
23.
IkotaH, NobusawaS, AraiH, KatoY, IshizawaK, HiroseT, and YokooH: Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Brain Tumor Pathol, 2015; 32:237–244.
24.
LiuX, OgasawaraS, KanekoMK, OkiH, HozumiY, GotoK, TakagiM, and KatoY: A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. Biochem Biophys Res Commun, 2015; 459:636–642.
25.
OhkaF, ItoM, RanjitM, SengaT, MotomuraA, MotomuraK, SaitoK, KatoK, KatoY, WakabayashiT, SogaT, and NatsumeA: Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol, 2014; 35:5911–5920.
26.
SabitH, NakadaM, FurutaT, WatanabeT, HayashiY, SatoH, KatoY, and HamadaJ: Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence. Brain Tumor Pathol, 2014; 31:242–246.
27.
OgasawaraS, KanekoMK, TsujimotoY, LiuX, and KatoY: Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132 L and IDH2-R172 M mutations. Monoclon Antib Immunodiagn Immunother, 2013; 32:377–381.
28.
KwonMJ, KimST, KongDS, LeeD, ParkS, KangSY, SongJY, NamDH, KatoY, ChoiYL, and SuhYL: Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri. Brain Pathol, 2012; 22:307–317.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
